Drug Type Small molecule drug |
Synonyms Balcinrenone/达格列净, Balcinrenone达格列净 |
Target |
Action modulators, inhibitors |
Mechanism MR modulators(Mineralocorticoid receptor modulators), SGLT2 inhibitors(Sodium/glucose cotransporter 2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC24H35ClO9 |
InChIKeyGOADIQFWSVMMRJ-UPGAGZFNSA-N |
CAS Registry960404-48-2 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Heart Failure | Phase 3 | United States | 12 Apr 2024 | |
Heart Failure | Phase 3 | Japan | 12 Apr 2024 | |
Heart Failure | Phase 3 | Argentina | 12 Apr 2024 | |
Heart Failure | Phase 3 | Australia | 12 Apr 2024 | |
Heart Failure | Phase 3 | Austria | 12 Apr 2024 | |
Heart Failure | Phase 3 | Brazil | 12 Apr 2024 | |
Heart Failure | Phase 3 | Bulgaria | 12 Apr 2024 | |
Heart Failure | Phase 3 | Canada | 12 Apr 2024 | |
Heart Failure | Phase 3 | Chile | 12 Apr 2024 | |
Heart Failure | Phase 3 | Colombia | 12 Apr 2024 |